Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia
Executive Summary
Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency
You may also be interested in...
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.
Chart: Obesity: Three New Drug Candidates Promise A New Dawn
Arena is positioning its pending anti-obesity NME lorcaserin as the cure for the obesity market hangover induced by the troublesome side effect profiles associated with earlier Rx weight loss products.